Compare Novo Nordisk A/S (NVO) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs STMicroelectronics NV — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while STMicroelectronics NV trades at $65.14 (market cap $55.80B). The key difference: Novo Nordisk A/S is far larger — about 4× STMicroelectronics NV's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | STM | |
|---|---|---|
Market Cap | $220.53B | $55.80B |
Sector | Health | Financials |
52-Week High | $71.70 | $79.91 |
52-Week Low | $35.29 | $21.20 |
Enterprise Value | $239.49B | $54.01B |
Dividend Yield | 3.63% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
STM stock trades at $65.43, up 5.43% in the past 24 hours, with a bearish technical signal and mixed earnings history. The company shows declining revenue and net income margins but maintains positive cash flow from operations. Recent news highlights AI partnerships and automotive chip demand as potential growth drivers.
Outlook remains cautious due to elevated P/E ratio of 386.13 and recent earnings misses, though analyst consensus is bullish with a $72.33 price target. Key risks include semiconductor cycle volatility and execution challenges in maintaining profitability amid revenue pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
